- Hot Flashes
- Neurokinin 1 Receptor Antagonist
- Refractory Vasomotor Symptoms of Menopause (Hot Flashes)
- Second-line option when hormonal therapy is contraindicated
- Cirrhosis
- Severe renal Impairment (including end-stage renal disease)
- Neurokinin 3 Receptor Antagonist
- Small molecule NK3 Receptor Antagonist
- Blocks neurokinin B (NKB) at the infundibular nucleus of the Hypothalamus
- Neurokinin B (NKB) regulates temperarture
- Blockade can decrease Vasomotor Symptoms of Menopause (Hot Flashes)
- Fezolinetant (Veozah)
- Cost: $550 per month when released in 2023
- Fezolinetant (Veozah) 45 mg orally daily (with or without food)
- Obtain baseline hepatic panel prior to starting, then in 3, 6 and 9 months
- Stop periodically to assess continued need
- Fezolinetant 45 mg daily reduces Hot Flashes by 2 to 3 per day
- Less effective than hormonal therapy for Vasomotor Symptoms of Menopause
- Similar to SNRIs, SSRIs and Gabapentin in hot flash reduction
- Was not studied in women age >65 years prior to release
-
CYP1A2 Inhibitors (e.g. Allopurinol, Omeprazole, Fluvoxamine, Cimetidine)
- Increase Fezolinetant levels